Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent
 influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV)
 containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent
 influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2)
 vaccines in producing protection against four strains of influenza virus.

 Primary Objective:

 -  To demonstrate that QIV-ID induces an immune response (as assessed by hemagglutination
 inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates) that is
 non-inferior to responses induced by TIV-ID1 and TIV-ID2 for the 4 virus strains at 28
 days post-vaccination.

 Secondary Objectives:

 -  To demonstrate that each B strain in QIV-ID induces an immune response (as assessed by
 HAI GMTs and seroconversion rates) that is superior to the response induced by the
 TIV-ID that does not contain the corresponding B strain.

 -  To describe the rate of post-vaccination seroprotection induced by QIV-ID and TIV-ID.

 -  To describe post-vaccination immunogenicity stratified by age (18-49 years and 50-64
 years), race, ethnicity, gender, previous vaccination status, and baseline
 seropositivity status.

 -  To describe the safety profile for subjects who receive QIV-ID and TIV-ID.

 Observational Objectives:

 -  To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 2 or
 Grade 3 solicited systemic reactions combined

 -  To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 3
 solicited injection site reactions combined.
All participants will receive a single dose of their assigned vaccine on Day 0. A subset of
 the participants will be assessed for immunologic response on Day 0 before vaccination and
 Day 28 after vaccination. All subjects will be monitored for safety for up to 6 months after
 vaccination.
Inclusion Criteria:

 -  Aged 18 through 64 years on the day of inclusion

 -  Informed consent form (ICF) has been signed and dated

 -  Able to attend all scheduled visits and to comply with all trial procedures. Exclusion
 Criteria:

 -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
 non-childbearing potential, a female must be post-menopausal for at least 1 year,
 surgically sterile, or using an effective method of contraception or abstinence from
 at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)

 -  Participation at the time of trial enrollment (or in the 4 weeks preceding the trial
 vaccination) or planned participation during the present trial period in another
 clinical trial investigating a vaccine, drug, medical device, or medical procedure

 -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned
 receipt of any vaccine in the 4 weeks following trial vaccination

 -  Vaccination against influenza in the past 6 months

 -  Receipt of immune globulins, blood or blood-derived products in the past 3 months

 -  Known or suspected congenital or acquired immunodeficiency; or receipt of
 immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
 within the preceding 6 months; or long-term systemic corticosteroid therapy
 (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

 -  Known systemic hypersensitivity to any of the vaccine components, or history of a
 life-threatening reaction to the vaccine used in the trial or to a vaccine containing
 any of the same substances

 -  History of thrombocytopenia

 -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion

 -  Deprived of freedom by an administrative or court order, or in an emergency setting,
 or hospitalized involuntarily

 -  Current alcohol abuse or drug addiction

 -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
 interfere with trial conduct or completion

 -  Identified as an Investigator or employee of the Investigator or trial center with
 direct involvement in the proposed trial, or identified as an immediate family member
 (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with
 direct involvement in the proposed trial

 -  Personal or family history of Guillain-Barré Syndrome

 -  Neoplastic disease or any hematologic malignancy (except localized skin or prostate
 cancer that is stable at the time of vaccination in the absence of therapy, and
 subjects who have a history of neoplastic disease and who have been disease free for ≥
 5 years.